FDA Advisors Back AstraZeneca's Truqap Combo

What Is Truqap and How Does It Treat Prostate Cancer?

Capivasertib, marketed as Truqap by AstraZeneca, is a first-in-class oral inhibitor of all three isoforms of AKT — a serine/threonine kinase central to the PI3K/AKT/mTOR signaling pathway. This pathway governs cell growth, survival, and metabolism, and is one of the most frequently dysregulated networks in human cancer. When PTEN, a tumor suppressor that normally restrains AKT activity, is lost or inactivated, AKT signaling becomes constitutively active, fueling tumor proliferation and resistance to standard therapies.

In metastatic castration-resistant prostate cancer (mCRPC), PTEN loss occurs in roughly 40–50% of advanced cases and is associated with poorer outcomes on androgen receptor-targeted therapy alone. Combining capivasertib with abiraterone — a CYP17 inhibitor that suppresses androgen synthesis — addresses two convergent oncogenic drivers simultaneously. Truqap is already FDA-approved in HR-positive, HER2-negative breast cancer with PIK3CA, AKT1, or PTEN alterations based on the CAPItello-291 trial, establishing the clinical credibility of the AKT-blockade approach.

Why Did the ODAC Vote Favor a Biomarker-Restricted Approval?

The CAPItello-281 trial, which evaluated capivasertib plus abiraterone in mCRPC, showed that progression-free survival benefit was driven primarily by the PTEN-deficient subgroup. In the broader all-comers population, gains were more modest, and the combination carries additional toxicities — notably hyperglycemia, diarrhea, and rash — that are characteristic of AKT pathway inhibition. ODAC's biomarker-restricted recommendation reflects regulators' increasing reluctance to approve combination regimens in unselected populations when the incremental benefit is concentrated in a molecularly defined subset.

This pattern mirrors recent FDA decisions in oncology, including the agency's pushback against tissue-agnostic approvals lacking strong biomarker rationale. For patients, a PTEN-restricted label means PTEN immunohistochemistry or genomic testing will become a gating step before treatment — adding diagnostic complexity but improving the likelihood that those who receive the drug actually benefit. AstraZeneca's strategy of building Truqap as a pan-tumor AKT-pathway franchise depends on these biomarker-driven approvals stacking across breast, prostate, and potentially other tumor types.

What Does This Mean for Prostate Cancer Treatment Going Forward?

Prostate cancer treatment has historically lagged behind breast cancer and lung cancer in adopting biomarker-driven therapy selection. The likely approval of capivasertib plus abiraterone for PTEN-deficient mCRPC accelerates that transition, joining PARP inhibitors (olaparib, rucaparib) for BRCA-mutated disease and pembrolizumab for MSI-high tumors as targeted options. Comprehensive genomic profiling at the time of metastatic diagnosis is becoming a clinical standard rather than a research exercise.

For health systems, the implications include expanded molecular pathology capacity, payer coverage decisions for testing, and patient education around what biomarker results mean for treatment options. Oncology guidelines from groups such as the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) are expected to incorporate the new combination once the FDA finalizes its decision, with PTEN testing recommended at progression on first-line therapy.